Loading
Life sciences · Journal article
Frontiers in Immunology · November 4, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Chikungunya virus (CHIKV), a re-emerging mosquito-borne alphavirus, has transitioned from an endemic pathogen to a global public health threat. In May 2026, the World Health Organization’s second rapid risk assessment classified the global public health risk of CHIKV transmission as moderate. Although two vaccines (IXCHIQ ® and VIMKUNYA ® ) have been authorized in selected countries, no antiviral therapy has been approved, and supportive care remains the mainstay of clinical management. We synthesize current knowledge of CHIKV epidemiology, replication, host immune signaling, and immune evasion, together with the developmental landscape of vaccines and antivirals. Through a critical appraisal of available evidence, we propose a hierarchical evidence-weighting framework that distinguishes in vivo mechanistic findings, cell-line observations, and human validation, and we highlight the stage-dependent functions of cytokines. Finally, we outline unresolved questions in chronicity, antiviral development, next-generation vaccine design and optimization, and cross-regional public health coordination, with particular emphasis on bridging the evidence gap between animal models and human infection.